雄激素受体是黑色素瘤向药物耐药性的决定因素
Anastasia Samarkina1, Markus Kirolos Youssef1, Paola Ostano2
1Department of Immunobiology, University of Lausanne, Épalinges, Switzerland.
Nature communications
|October 14, 2023
概括
向雄激素受体 (AR) 可以克服黑色素瘤中对BRAF/MEK抑制剂 (BRAFi/MEKi) 的耐药性. 抑制AR抑制瘤生长并增强抗癌免疫反应在耐性黑色素瘤.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 黑色素瘤治疗通常涉及BRAF/MEK抑制剂 (BRAFi/MEKi),但耐药性迅速发展.
- BRAFi/MEKi耐药性与免疫检查点治疗的不良结果有关.
- 雄激素受体 (AR) 活性对于黑色素瘤细胞增殖至关重要.
研究的目的:
- 研究雄激素受体 (AR) 在黑色素瘤中BRAF/MEK抑制剂 (BRAFi/MEKi) 耐药性的作用.
- 确定AR抑制是否可以克服BRAFi/MEKi耐药性并改善治疗结果.
主要方法:
- 在敏感和耐性黑色素瘤细胞中评估AR表达.
- 利用了AR的遗传和药理抑制.
- 分析了与AR活性相关的转录性变化.
- 在体内评估AR抑制对瘤生长和免疫细胞透的影响.
主要成果:
- 在抗BRAFi的黑色素瘤细胞中和在敏感细胞中暴露于BRAFi时,AR表达显著增加.
- 增高的AR表达足以诱导BRAFi耐药性,改变基因表达特征 (例如EGFR,SERPINE1).
- 抑制AR逆转了与耐药性相关的基因表达,抑制了瘤增殖,并促进了CD8+ T细胞透和癌细胞杀死.
结论:
- 雄激素受体 (AR) 在黑色素瘤中对BRAF/MEK抑制剂 (BRAFi/MEKi) 耐药性的发展和维持中发挥着关键作用.
- 向AR是一种有希望的联合治疗策略,可以克服BRAFi/MEKi耐药性并增强黑色素瘤的抗瘤免疫力.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K


